Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Total Liabilities (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Total Liabilities for 7 consecutive years, with $242.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Liabilities fell 34.42% to $242.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $242.8 million, a 34.42% decrease, with the full-year FY2025 number at $242.8 million, down 34.42% from a year prior.
  • Total Liabilities was $242.8 million for Q4 2025 at Beam Therapeutics, down from $345.1 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $647.7 million in Q4 2021 to a low of $242.8 million in Q4 2025.
  • A 5-year average of $451.8 million and a median of $426.7 million in 2024 define the central range for Total Liabilities.
  • Peak YoY movement for Total Liabilities: soared 398.21% in 2021, then tumbled 34.42% in 2025.
  • Beam Therapeutics' Total Liabilities stood at $647.7 million in 2021, then fell by 6.09% to $608.2 million in 2022, then decreased by 21.35% to $478.4 million in 2023, then fell by 22.6% to $370.3 million in 2024, then crashed by 34.42% to $242.8 million in 2025.
  • Per Business Quant, the three most recent readings for BEAM's Total Liabilities are $242.8 million (Q4 2025), $345.1 million (Q3 2025), and $344.3 million (Q2 2025).